Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy

Abstract Despite more than 2 years having elapsed since the onset of SARS-CoV-2 pandemic, a level of hesitation around increased SARS-CoV-2 vaccine toxicity in cancer patients receiving immunotherapy (IO) remains. This hesitation stems from the idea that IO agents could elicit an overwhelming immune...

Full description

Bibliographic Details
Main Authors: Pavlina Spiliopoulou, Helena J. Janse van Rensburg, Lisa Avery, Vathany Kulasingam, Albiruni Razak, Philippe Bedard, Aaron Hansen, Andrzej Chruscinski, Ben Wang, Maria Kulikova, Rachel Chen, Vanessa Speers, Alisa Nguyen, Jasmine Lee, Bryan Coburn, Anna Spreafico, Lillian L. Siu
Format: Article
Language:English
Published: Nature Publishing Group 2023-01-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-05548-4

Internet

https://doi.org/10.1038/s41419-022-05548-4

Similar Items